Cipla Teams Up with Qilu Pharmaceutical for Keytruda® Biosimilar in the U.S.

Cipla Forms Strategic Alliance with Qilu Pharmaceutical

In a significant development in the pharmaceutical industry, Cipla Limited, through its fully owned subsidiary, Invagen Pharmaceuticals, has announced a strategic partnership with Qilu Pharmaceutical Co., Ltd. This collaboration focuses on the exclusive licensing and supply of QL2107, a biosimilar of the well-known cancer treatment Keytruda® (pembrolizumab), specifically for the U.S. market.

Partnership Overview

As outlined in the agreement, Qilu Pharmaceutical will take charge of the developmental aspects, regulatory registration, and the supply chain for the biosimilar product. Meanwhile, Cipla USA Inc. will utilize its robust commercial presence and expertise in the U.S. to lead the product's market introduction.

This partnership emphasizes a shared commitment from both companies to alleviate the rising incidence of cancer and improve access to advanced biologic therapies for patients.

Leadership Perspectives

The significance of this partnership was highlighted by Achin Gupta, Managing Director and Global CEO of Cipla, who stated, “This partnership exemplifies our confidence in the long-term potential of biosimilars. It is a strategic step toward enhancing our oncology-focused portfolio. By merging Qilu's development expertise with our commercial capabilities, we aim to facilitate broader access to high-quality biologics for patients across our markets.”

Further insights were shared by Marc Falkin, CEO of Cipla North America. He expressed excitement about the collaboration, aligning it with their strategy to develop a more extensive biosimilar portfolio in the upcoming fiscal years. He mentioned, “Our established commercial capabilities place us in an excellent position to launch QL2107 successfully, once we receive regulatory approval. We are dedicated to ensuring this treatment becomes accessible to patients in need, all while reducing treatment costs.”

Hanchang Zhang, General Manager of Qilu Pharmaceutical, also expressed enthusiasm about the partnership. He remarked, “We are thrilled to collaborate with Cipla on QL2107. Combining our research, development, and manufacturing strengths with Cipla's commercial expertise in the U.S. will allow us to introduce a high-quality, affordable biosimilar to pembrolizumab for American patients.”

Cipla and Qilu Pharmaceutical Background

Cipla Limited

Founded in 1935, Cipla has grown into a prominent global pharmaceutical entity, committed to sustainable growth and a solid portfolio of complex generics. With substantial operations in India, South Africa, and North America, Cipla ranks highly in the pharmaceutical market, focusing on critical therapeutic areas like respiratory, anti-retroviral, and oncology segments. Boasting 48 manufacturing sites worldwide, Cipla caters to over 70 markets, emphasizing its purpose of enhancing patient access through affordable medicines.

Qilu Pharmaceutical

Established in 1958, Qilu Pharmaceutical ranks among the leading vertically integrated pharmaceutical companies in China and boasts a robust pipeline, having achieved numerous approvals from regulatory bodies like the FDA. With significant investments in research and development, Qilu is dedicated to producing high-quality pharmaceuticals to improve global health outcomes. The company currently exports to over 110 countries, reflecting its commitment to expanding its reach and impact.

Conclusion

The alliance between Cipla and Qilu Pharmaceutical marks a pivotal moment in enhancing access to advanced cancer treatments in the U.S. through biosimilars. As both companies work towards maximizing their combined strengths, they aim to make significant strides in the oncology sector, ultimately benefiting patients and healthcare systems alike. This partnership sets a promising precedent in the pharmaceutical landscape, outlining a path forward for more strategic collaborations aimed at patient care and accessibility in the realm of healthcare.